Dr. Fitzpatrick is a Clinical Cytogeneticist and Molecular Geneticist with a focus in Constitutional disorders. Her clinical practice and diagnostic expertise also include Cytogenetics and Molecular Genomics of neoplastic disorders including hematologic malignancies and solid tumors.
University of Chicago
ABMGG Clinical Fellowship - Molecular Genetics
2017
University of Chicago
ABMGG Clinical Fellowship - Cytogenetics
2007
University of Illinois at Chicago
PhD - Molecular Genetics
2003
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 Jun 18; 14(1):99.
PMID: 38890297
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
PMID: 38150184
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.
PMID: 38150184
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023 Dec 01.
PMID: 38039510
Clinicopathologic Analysis and Molecular Profiling of Ovarian Steroid Cell Tumors.
Clinicopathologic Analysis and Molecular Profiling of Ovarian Steroid Cell Tumors. Am J Surg Pathol. 2023 12 01; 47(12):1398-1408.
PMID: 37796179
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors.
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
PMID: 36655425
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation.
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2023 03 28; 7(6):963-970.
PMID: 35973200
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases. Hum Pathol. 2023 04; 134:124-133.
PMID: 36592877
Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation.
Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. Blood Adv. 2022 Aug 16.
PMID: 35973200